CD38 protein, which was discovered in 1980, is a type II transmembrane glycoprotein with a size of 46 kDa. The ligand of CD38 is CD31, also known as PECAM-1, which is aRead More…
In a new study, researchers from Humabs Biomed SA and the University of Washington found that an antibody that suppresses the associated coronavirus was identified for the first time in a bloodRead More…
Researchers from Charité-Universitätsmedizin Berlin, Berlin Institute of Health and Deutsches Rheuma-Forschungszentrum, together with other scientists, have shown how microbes help the immune system respond to pathogens. Without the relevant mediators, the metabolicRead More…
In a study published in Nature, scientists from St. Jude’s Children’s Research Hospital and other institutions have developed a new treatment strategy to effectively enhance cancer immunotherapy, which may effectively slow tumorRead More…
Incidence of lung cancer Lung cancer has the highest incidence of cancer in the world. According to WHO’ statistics, there are an estimated 18.1 million new cancer patients worldwide in 2018, ofRead More…
The high cost of cancer drugs makes it difficult for public and private health care systems to provide patients with up-to-date treatment. If this trend continues, it will be increasingly difficult forRead More…
According to the World Health Organization (WHO), cancer is the second leading cause of death in the world. In 2018 alone, 9.6 million people worldwide died of cancer, accounting for about 1/6Read More…
Most CAR-T cell therapies require targeting cancer cell-specific antigens. Now, there is a new way to target the environment around the tumor, which comes from nanobodies naturally produced by free alpacas, camelsRead More…
Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the nanobody drug Cablivi (caplacizumab), combined with plasma exchange and immunosuppressive therapy. For the treatment ofRead More…